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Letter to the Editor: 
We applaud the authors of “Prevalence of metabolic syndrome in sub-Saharan Africa: a 
systematic review and meta-analysis” for their efforts in gathering and publishing this 
evidence. In this systematic and meta-analysis, Faijer-Westerink and colleagues sought to 
estimate the prevalence of metabolic syndrome (MetS) in sub-Saharan Africa (SSA), with 
further evaluation in subgroups of the population.[1] Based on a total of 65 studies, the 
overall pooled prevalence of MetS according to different diagnostic criteria ranged widely 
from 11.1 to 23.9%. In subgroup analysis, prevalence estimates seem to be highest in 
women, urban populations and Southern Africa. Based on their findings, the authors 
concluded that MetS was not rare in SSA and highlighted the need for public health 
intervention efforts to curb the burden of MetS. The strengths of this meta-analysis include 
the novelty, being the first attempt at summarising prevalence estimates of MetS across the 
SSA region; the comprehensive search strategy across major databases; and 
comprehensive analyses which included use of the Freeman-Tukey variance stabilising 
double arcsine transformation to account for data with low rates, detailed exploration of 
heterogeneity, assessing for small study effects, and several sensitivity analyses to test the 
robustness of the results. There are however some limitations which deserve discussion. 
Caution needs to be exercised in generalising the findings to the whole of the SSA region. Of 
the 48 SSA countries, the 65 eligible studies were based in only 14 (29%) of these countries, 
with the majority from West Africa (especially from Nigeria). Though the authors indicated 
that caution with generalisability is warranted, they also stated that the pooled prevalence 
estimate of MetS was fairly representable. The coverage of a few countries in some of the 
African regions cannot imply generalisability of the data. Second, there was substantial 
heterogeneity across studies in the majority of pooled combinations (I2>90% for each), 
hence it is debatable if pooled estimates should have been presented given that the 
presence of excessive heterogeneity makes pooling of data somewhat controversial. We are 
aware that the authors made great efforts to identify the possible sources of heterogeneity. 




studies were conducted in the same area, hence there was the potential of overlapping 
participants and therefore the possibility of double-counting during pooling.  
 
Nevertheless, despite the limitations, the findings of Faijer-Westerink and colleagues[1] are 
very relevant and timely. The authors should be commended for this fine addition to the 
existing evidence - providing more evidence on the changing pattern of non-communicable 
disease (NCD) occurrence in SSA. Though communicable diseases (such as HIV/AIDS and 
tuberculosis) are major sources of morbidity and mortality in SSA, it is projected that NCDs 
such as cardiovascular diseases (CVDs) and type 2 diabetes, will overtake infectious 
diseases with regards to morbidity and mortality by the year 2030.[2] CVDs are the number 
one cause of death globally and constitute a major public health burden.[3] Currently, 
developing countries (such as in SSA) contribute a greater share to the global burden of 
CVD than developed countries.[3] MetS characterized by a constellation of metabolic 
disorders, is a major risk factor for type 2 diabetes and CVD.[4] There is a wealth of cross-
sectional data showing the prevalence of potential risk factors for CVD and other NCDs in 
SSA[5, 6] and which has led to better understanding of the distribution of NCDs and their 
known risk factors. However, there is a need for reliable data on how risk factors change 
over time and how they relate to NCD outcomes. Prospective cohort designs are the solution 
and they can be used to study complex disease outcomes and multiple risk factors and are 
very crucial in understanding disease aetiology, course and prognosis, and can inform the 
development of long-term prevention strategies.[2, 7] Given the large and growing disease 
burden due to NCDs, Holmes and colleagues have urgently called for the establishment of 
large well-designed longitudinal cohorts in SSA.[2] The current findings by Faijer-Westerink 
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